It is essential for every person who might ever be a patient to participate in the discussion of pertinent issues related to the implementation and full utilization of molecular medicine, combination therapies, and seriously ill patients’ ability to access experimental therapies.  Below are these issues, as they relate to each topic.

Legislative & Implementational Topics

Molecular Medicine

• Two Ways for Clinical Implementation, which is best?
• Who pays for this method? (study outline of a test to discover cost-effectiveness of each approach)

Combination Products

• Incentives to offer – Are they necessary?  Should society provide them anyway to speed the process of dvlpt?

Accessing Experimental Therapies

Expanded Access / Compassionate Use

• Direct Cost recovery is uneconomical when it comes to being sustainable, but do we need and should we change this?
• FDA has power to say “No” – should they?  Or should the right be exclusively up to the patient and the therapy sponsor?
• Defining when a patient is seriously or terminally ill; repercussions for those who lie.

Clinical Trials

• Should you have control groups for terminal patients?
• New outline for clinical trials - Clinical trial protocol changes to best incorporate molecular-based medicine

Within Innovation and Choice

• Marketplace for Innovation - subsequently providing you with an infinite level of resources and allowing you to inquire about their services and INVEST in them (furthering our Venture Fund idea to empower you to make a difference)
• Online Platform to facilitate discussion, education, community, and empowerment

Outside of Innovation and Choice

• CT.gov Suggestions
• OpenCongress.org Suggestions

Venture Fund to fund any of these projects or outside project